Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia

Table 2 Correlation of PB blast reduction ratio (PBRR) with treatment response

	PB blast reduction ratio (Log10) ( ± SD)
	Day 3	Day 5	Day 7	Day 9
CR (n = 67)	1.09 ± 0.62	2.49 ± 0.92	3.41 ± 1.02	3.92 ± 1.28
NCR (n = 29)	0.70 ± 0.53	1.70 ± 0.70	2.49 ± 0.95	2.91 ± 1.13
P value	0.005	<0.0001	<0.0001	<0.0001
MRD (+) n = 23)	1.05 ± 0.60	2.43 ± 1.05	3.19 ± 1.11	3.62 ± 1.41
MRD (−) (n = 29)	1.25 ± 0.64	2.69 ± 0.78	3.19 ± 1.11	4.15 ± 1.13
P value	0.266	0.334	0.162	0.157
Relapse (+) (n = 25)	0.85 ± 0.45	2.00 ± 0.68	2.83 ± 0.78	3.15 ± 1.02
Relapse (−) (n = 54)	1.12 ± 0.67	2.59 ± 0.93	3.57 ± 0.98	4.16 ± 1.19
P value	0.066	0.005	0.001	0.0005
Early relapse^a (+) (n = 16)	0.80 ± 0.45	1.91 ± 0.80	2.76 ± 0.81	3.14 ± 1.10
Early relapse^a (−) (n = 63)	1.10 ± 0.65	2.52 ± 0.89	3.48 ± 0.97	4.02 ± 1.19
P value	0.094	0.017	0.008	0.009

CR achieved complete remission after one course of induction therapy, NCR not achieved complete remission, MRD minimal residual disease. ^aEarly relapse: hematologic relapse within 6 months.

ISSN: 1756-8722